Sucampo Pharmaceuticals

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Sucampo Pharmaceuticals ( SCMP) is focused on the discovery, development and commercialization of drugs based on prostones to treat gastrointestinal, ophthalmologic, CNS, vascular and respiratory diseases as well as other potential therapeutic applications. This stock is trading up 5.5% to $5.10 in recent trading.

Today's Range: $4.80-$5.10

52-Week Range: $2.96-$8.50

Volume: 15,000

Three-Month Average Volume: 60,960

From a technical perspective, SCMP is soaring back above its 50-day moving average of $4.93 here with light volume. This stock has been on fire since the start of August, with shares trending higher from $3.78 to its current price of $5.10.

Traders should now look for long-biased trades in SCMP as long as it's trending above some near-term support at $4.50 with strong upside volume flows, or as long as its trending above its 50-day. I would consider any upside volume day that registers near or above 60,960 shares as bullish. If SCMP can hold those levels and continue to push higher, then this stock will setup to trigger a major breakout trade. That trade will hit once SCMP takes out its 200-day moving average of $5.95 with high volume. Any high-volume move over $5.95 will setup SCMP to re-fill its previous gap down. If SCMP gets into that gap, then this stock could easily tag $7 in the near future.

To see more stocks under $10 that are making notable moves higher today, check out the Stocks Under $10 Moving Higher portfolio on Stockpickr.

-- Written by Roberto Pedone in Winderemere, Fla.


Follow Stockpickr on Twitter and become a fan on Facebook.
At the time of publication, author had no positions in stocks mentioned.

Roberto Pedone, based out of Windermere, Fla., is an independent trader who focuses on stocks, options, futures, commodities and currencies. He is also an outside contributor to and maintains the website, which he sold to Blue Wave Advisors in 2008. Roberto studied International Business at The Milwaukee School of Engineering, and he spent a year overseas studying business in Lubeck, Germany.

If you liked this article you might like

Winning FDA Approval Isn't Always a Win

Will Allergan's Deal With Tribe Hold Up?

2 Small Biotechs Under $5 May Be Bargains

Resist All the Dow 22K Hoopla: Cramer's 'Mad Money' Recap (Wednesday 8/2/17)

3 Biotech Stocks on Readers' Minds